David Harmon, MD


Office Address
Massachusetts General Hospital Cancer Center
Center for Sarcoma and Connective
Tissue Oncology
55 Fruit Street, Yawkey 7
Boston, MA 02114

Orthopaedic Oncology
Francis Hornicek, MD, PhD Director & Surgeon
Frank X. Pedlow, Jr. MD Surgeon
Kevin Raskin, MD Surgeon
Joseph Schwab, MD Surgeon

Al Ferreira, RN Nurse Coordinator
Anne Fiore, NP Nurse Practitioner

Radiation Oncology
Yen-Lin Chen, MD Radiation Oncologist
Thomas DeLaney, MD Radiation Oncologist
Norbert Liebsch, MD, PhD Radiation Oncologist

Medical Oncology
Edwin Choy, MD, PhD Medical Oncologist
David Harmon, MD Medical Oncologist
Scott Plotkin, MD, PhD Medical Oncologist
Gregory Cote, MD Medical Oncologist
Judianne Henderson, NP Nurse Practitioner

Frederick Barker, MD Neurosurgeon
Lawrence Borges, MD Neurosurgeon
William Curry, MD Neurosurgeon

Surgical Oncology
John Mullen, MD Surgeon

Plastic Surgery
William Gerald Austen, MD Plastic Surgeon
Eric Liao, MD, PhD Plastic Surgeon

Susan Kattapuram, MD Radiologist
Daniel Rosenthal, MD Radiologist

G. Petur Nielsen, MD Pathologist

Stacey Gray, MD Otolaryngologist
Eric Holbrook, MD ENT Surgeon
Derrick Lin, MD ENT Surgeon
James Rocco, MD, PhD ENT Surgeon
Benjamin S. Bleier, M.D. ENT Surgeon

Francis Hornicek, MD, PhD Co-Director
Ramnik Xavier, MD Co-Director
Zhenfeng Duan, MD, PhD
Joseph Schwab, MD Surgeon

Click here for the Contact Us page


"Although we still lack medicines that can be counted on to shrink or slow the growth of chordomas, we are following a variety of exciting leads. Our goal is to keep studying the biology of chordomas to identify targets for chemotherapy and then to make clinical trials available to those who need more than surgery and radiation. "

David Harmon, MD

Clinical Interests

Sarcoma; Lymphoma of Bone; Multiple Myeloma; Immune Cytopenias; General Hematology

MD Degree: Harvard Medical School

Postdoctoral Training
Residency: Rhode Island Hospital, Providence, RI
Fellowship: Hematology & Oncology, Massachusetts General Hospital, Boston, MA

Board Certification
Internal Medicine

Academic Appointments
Assistant Professor, Harvard Medical School


Kraybill WG, Harris J, Spiro IJ, Ettinger DS, DeLaney TF, Blum RH, Lucas DR, Harmon DC, Letson GD, Eisenberg B; Radiation Therapy Oncology Group Trial 9514. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol. 2006 Feb 1;24(4):619-25.

Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 2004 Dec;(429):286-91.

DeLaney TF, Spiro IJ, Suit HD, Gebhardt MC, Hornicek FJ, Mankin HJ, Rosenberg AL, Rosenthal DI, Miryousefi F, Ancukiewicz M, Harmon DC. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27.

Fidias P, Spiro I, Sobczak ML, Nielsen GP, Ruffolo EF, Mankin H, Suit HD, Harmon DC. Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys. 1999 Dec 1;45(5):1213-8.

Click here for PubMed listings for Dr. Harmon

As a medical oncologist, Dr. Harmon has focused on the care of patients with bone and soft tissue tumors.  Because the specialized surgical and radiotherapy expertise of MGH draws patients from all over the world, his clinical practice has included many otherwise rare patients with unresectable or metastatic chordoma. 

He has long seen the need for effective new therapies and has participated in clinical trials to develop chemotherapies.  Now a critical mass of researchers has directed their attention towards understanding the basic biology of chordoma and to finding new targets for therapy.

Collaborative efforts with other centers are developing a series of clinical trials.   Together with Dr. Choy and the rest of the clinical research team he will push these efforts to find cures.



Home Site Map